Transcript 2014 Emerging Science Program Schedule

2014 Emerging Science Program Schedule
Following is the schedule of Emerging Science abstracts to be presented at the 2014 AAN Annual Meeting. Abstracts
qualify for Emerging Science presentations by having key aspects of research conducted after the October 28th abstract
submission deadline and must be new and of sufficient scientific importance to warrant expedited presentation and
publication.
The Science Committee is committed to presenting the best neuroscientific research at the Annual Meeting so we are
excited to announce that we are accepting 10 abstracts for dual presentation this year and 14 abstracts as poster
presentations. The 10 dual presentation abstracts will be featured in data blitz format during the first 30 minutes of the
Emerging Science Platform session from 6:15 p.m. to 6:45 p.m., followed by poster presentations in the same room from
6:45 p.m. to 7:30 p.m. A total of 14 poster presentation abstracts will be included in Poster Session 3 on Tuesday, April
29 from 3:00 p.m. to 6:30 p.m. and Poster Session 4 on Wednesday, April 30 from 7:30 a.m. to 11:00 a.m.
Emerging Science Platform Session – 6:15 p.m. – 7:30 p.m., Wednesday, April 30, 2014
001- “Drisapersen treatment for Duchenne muscular dystrophy: results of a 96-week follow-up of an open-label
extension study following two placebo-controlled trials” Nathalie Goemans, Leuven, Belgium
002- “Selective Inhibition of Meningeal Nociceptors by Botulinum Neurotoxin Type A (BoNT-A): Therapeutic Implications
to Migraine and Other Pains” Rami Burstein, Boston, MA
003- “Asymptomatic carotid stenosis is associated with cognitive dysfunction” Moira Dux, Baltimore, MD
004- “A negative florbetaben PET scan reliably excludes amyloid pathology as confirmed by histopathology in a large
Phase 3 trial” Marwan Sabbagh, Scottsdale, AZ
005- “Coincident Alzheimer’s disease modifies alpha-synuclein pathology in Lewy body disease” Jon Toledo,
Philadelphia, PA
006- “Results of a Phase 2 Study of ISIS-SMNRx in Children with Spinal Muscular Atrophy” Claudia Chiriboga, New York,
NY
007- “Oral sialic acid extended release (SA-ER) stabilizes upper extremity muscle strength in human GNE myopathy: A
phase 2 study.” Zohar Argov, Jerusalem, Israel
008- “Alemtuzumab Improves Brain MRI Outcomes in Patients With Active Relapsing-Remitting Multiple Sclerosis: 3Year Follow-up of the CARE-MS Studies” Douglas Arnold, Montreal, Canada
009- “The Relationship Between Peripheral B-Cell Levels and MRI Disease Activity in Relapsing Remitting Multiple
Sclerosis (RRMS)” Daren Austin, Uxbridge, United Kingdom
010- “Prolonged-Release Fampridine Treatment and Walking Ability and Balance in Patients with Multiple Sclerosis:
Results of the Randomized, Double-Blind MOBILE Study” Jan Lycke, Gotebor, Sweden
Emerging Science Poster Presentations- Poster Session 3 – 3:00 p.m. – 6:30 p.m., Tuesday, April 29, 2014
P3.342- “Bumetanide Attenuates Neuronal Network Hyperexcitability and Improves Survival in a Mouse Model of
Tuberous Sclerosis” Hongyu Sun, Philadelphia, PA
P3.343- “SPP1 rs28357094 Genotype is Neither a Determinant of Duchenne Muscular Dystrophy (DMD) Disease
Progression Nor Useful as a Clinical Trial Outcome Covariate: Results From 3 Controlled Trials in DMD Subjects Amenable
to Exon 51 Skipping” Sarah Glass, Research Triangle Park, North Carolina
P3.344- “A Phase II Study to Assess Safety and Efficacy of Olesoxime (TRO19622) in 3-25 year Old Spinal Muscular
Atrophy (SMA) Patients” Eric Dessaud, Marseille, France
P3.345- “Elevated Neuroinflammatory Responses in a Mouse Model of Tuberous Sclerosis Complex (TSC)” Delia Talos,
Boston, MA
P3.346- “Autosomal-dominant Parkinsonism With a Novel MAPT Gene Mutation in a Specific Population of Central
Europe (South-Eastern Moravia, Czech Republic)” Petr Kanovsky, Olomouc, Czech Republic
P3.347- “A Novel Assay for Protein Analysis in Friedreich’s Ataxia (FRDA): Implications for Diagnosis and Clinical Trial
Design” Gabriela Raina, Buenos Aires, Argentina
P3.348- “Brain Regeneration: Mechanistic and Functional Characterization of Axolotl Pallium Regeneration” Salman
Bhai, Brookline, MA
Emerging Science Poster Presentations- Poster Session 4 – 7:30 a.m. – 11:00 a.m., Wednesday, April 30, 2014
P4.343- “Mortality is Greater in Persons With Non-amnestic Than With Amnestic Mild Cognitive Impairment. The Mayo
Clinic Study of Aging” Maria Vassilaki, Rochester, MN
P4.344- “Effect of Adjunctive Perampanel on Cognition in Adolescents With Inadequately Controlled Partial-Onset
Seizures” Kimford J. Meador, Stanford, CA
P4.345- “The POEM Study: Testing the Impact of a Digital Health Platform in U.S. Veterans with Epilepsy” John Hixson,
San Francisco, CA
P4.346- “The 2014 Certification of a Polio-Free India: Progress towards Global Polio Eradication” Farrah Mateen, Boston,
MA
P4.347- “Longitudinal Change in Quantitative Spinal Cord MRI in Multiple Sclerosis Patients: Preliminary Results of a 2year Study” Jiwon Oh, Baltimore, MD
P4.348- “Comparison and Correlation of Two Proposed PML Risk Stratification Biomarkers for Long-term Natalizumab
Treatment, Anti-JCV Antibody Index and L-selection (CD62L): A Retrospective Study.” Nicholas Schwab, Wuerzburg,
Germany
P4.349- “Perception of Analgesia in Narcotic Users with Chronic Pain: A Multi-Center Cross-Sectional Study Comparing
Genotype to Pain VAS (P.A.I.N. Study)” Tobore Onojjighofia, Baltimore, MD